K.AbeywardenaM.O'CallaghanN.LionettiL.et al (2019)
Keywords , MASH , GLP-1 receptor agonists , hepatic steatosis , metabolic dysfunction , tirzepatide , semaglutide , survodutide 0 2 INTRODUCTION Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), has emerged as the predominant hepatic pathology worldwide, impacting roughly twenty-five percent of the adult population [1,2]
although, oral supplementation with L-citrulline, a precursor for arginine biosynthesis, has been shown to be more efficient than oral L-arginine in increasing plasma L-arginine [Citation9], due to splanchnic catabolism of ingested L-Arginine [Citation24]
Come abbiamo spiegato prima, il nostro corpo sintetizza da solo questo amminoacido e, in generale, il suo consumo non necessario poich ne creiamo abbastanza per i nostri bisogni essenziali